By no means is Merck (MRK) out of the woods yet, but there may be a clearing coming up. The pharmaceutical giant, which offers a 4.1% dividend yield, has been a leading player in cholesterol drugs for years. Its blockbuster Zocor is now generic, but Merck has since come out with Vytorin. Vytorin is a powerful drug. It's a combination of two drugs, Zocor and Zetia. It's a pricey drug, but the cocktail aims to better prevent heart attacks, strokes